NYSEMaterialsChemicals - SpecialtySnapshot 2026-08-31
Reading ALB? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Albemarle is recovering with revenue growing from $1.1B in 2025-Q1 to $1.4B in 2026-Q1. Adjusted EBITDA rose from $267M to $664M in the same period. The company plans to keep capital spending flat around $550M to $600M in 2026. These show progress toward stabilizing and improving profitability.
Albemarle remains volatile and loss-making with a high PE of 55. Margins and earnings have been inconsistent, with recent misses and a sharp stock selloff. The turnaround may stall if revenue growth or EBITDA targets are not sustained.
The market prices in about 11% revenue growth and values the stock roughly 15% below our fair value of $152. Our fair value is 38% below the Street median, reflecting caution on profitability and execution risks.
Breaks if: Adjusted EBITDA falls below $900 million in FY26
Breaks if: Capital expenditures exceed $600 million or fall below $550 million in FY26
Annual revenue falls below $4.1 billion in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario with elements of volatility. The current thesis state indicates mixed progress in achieving financial targets, leading to a cautious outlook.
The market appears to reflect a premium valuation compared to peers, suggesting that some growth expectations are already built into the stock. However, there is a slight expectations gap, indicating that the market may not fully anticipate potential challenges.
Fundamentals may show gradual improvement as management focuses on maintaining revenue guidance and achieving adjusted EBITDA targets. However, the company's recent financial performance has been neutral, and risks remain elevated due to past earnings volatility.
The thesis hinges on several factors, including management's ability to maintain guidance, sector performance, and broader economic conditions such as inflation. Any negative guidance on future earnings could significantly impact sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company aims for strong EBITDA growth. It also maintains revenue guidance for 2026. However, there are concerns about revised earnings outlook. This could affect future revenue guidance.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, Albemarle's performance will depend on effective management execution and external market conditions. Not investment advice.
